Non-Hodgkin lymphoma Posts Page 2 on Medivizor
Navigation Menu

Non-Hodgkin lymphoma Posts on Medivizor

Is rituximab/bendamustine safer and more effective than R-CHOP in patients with grade 3A follicular lymphoma?

Posted by on Apr 18, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study investigated the effectiveness and safety of the R-B (rituximab, bendamustine) regimen versus the R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) regimen in patients with grade 3A follicular lymphoma (FL3A). This study concluded that R-B is better tolerated and more effective than R-CHOP, making it a...

Read More

What are the outcomes for lymphoma patients who received TECAM chemotherapy before a stem cell transplant?

Posted by on Apr 18, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study analyzed data from patients with Hodgkin’s lymphoma (HL) and non-Hodgkin’s lymphoma (NHL) who received TECAM (etoposide, thiotepa, cytarabine, cyclophosphamide, melphalan) chemotherapy before autoSCT (autologous stem cell transplantation). The authors concluded that TECAM is an effective pre-autoSCT regimen for...

Read More

What are the outcomes for B-cell lymphoma patients who receive salvage treatment for cancer that does not respond to R-CHOP chemotherapy?

Posted by on Apr 10, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study compared the outcomes of different salvage treatments in patients with aggressive B-cell non-Hodgkin lymphoma with PET-positive disease (remaining cancer cells) after R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) chemotherapy. This study concluded that B-cell NHL patients with PET-positive...

Read More

How safe and effective is the combination of ibrutinib, lenalidomide, and rituximab for relapsed or refractory mantle cell lymphoma?

Posted by on Mar 17, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study investigated the safety and effectiveness of ibrutinib (Imbruvica), lenalidomide (Revlimid), and rituximab (Rituxan) given together to patients with relapsed or refractory (not responding to treatment) mantle cell lymphoma (MCL). The authors conclude that this combination is effective in these patients, but not better than the...

Read More

Survival outcomes for patients with stage I follicular lymphoma

Posted by on Mar 17, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study looked at the outcomes for patients with stage I follicular lymphoma who had their tumors completely removed. The authors concluded that a total resection does not significantly improve patient outcomes after they have received other treatments. Some background Follicular lymphoma (FL) is a type of slow growing non-Hodgkin...

Read More

Low-dose radiotherapy for low-grade lymphoma: What are the outcomes?

Posted by on Mar 17, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study investigated the effectiveness, side effects, and relapse patterns of patients with low-grade (indolent; painless) follicular lymphoma (FL) or marginal zone lymphoma (MZL) after low-dose radiotherapy (LDRT). This study concluded that LDRT is an effective treatment in patients with low-grade disease and a low tumor burden. Some...

Read More

5 Things You Probably Didn’t Know About Your Adrenal Glands

5 Things You Probably Didn’t Know About Your Adrenal Glands

Posted by on Mar 15, 2018 in Benign prostatic hyperplasia, Blog, Breast cancer, Colorectal cancer, Coronary artery disease, Diabetes mellitus, Erectile dysfunction, Hodgkin's lymphoma, Hypertension, Infertility, Kidney stones, Leukemia, Lung cancer, Lymphoma, Melanoma, Multiple Myeloma, Non-Hodgkin lymphoma, Prostate cancer, Rheumatoid Arthritis, Stroke, Urinary incontinence, Urinary tract infection | 3 comments

The adrenal glands-which are also called suprarenal glands-are part of the endocrine system and are found on the top of each kidney. How the endocrine system hormones work Hormones secreted from glands of the endocrine system travel in the bloodstream to target cells. Target cells have receptors that are specific to each hormone. The hormones and receptors...

Read More

What are the long-term outcomes following bendamustine treatment?

Posted by on Mar 12, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study examined the long-term safety and effectiveness of bendamustine (Treanda) in lymphoma and leukemia. This study concluded that bendamustine is a safe and effective therapy for these patients. Some background Bendamustine has been shown to have high effectiveness and few side effects for a wide range of lymphomas. This drug is...

Read More

Effectiveness of autologous stem cell transplantation in elderly patients with lymphoma

Posted by on Mar 12, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study looked at the effectiveness of treating elderly lymphoma patients with autologous stem cell transplantation. The study concluded that autologous stem cell transplantation should be considered on an individual basis, and age should not automatically disqualify elderly patients.  Some background Patients with lymphoma...

Read More

Predicting ischemic heart disease and stroke in survivors of childhood cancer

Posted by on Mar 10, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study investigated the individual risk of ischemic heart disease and stroke through age 50 in 5-year survivors of childhood cancer. The authors concluded that these conditions can be reasonably predicted using information available after childhood cancer therapy. Some background For the 400,000 childhood cancer survivors in the...

Read More

Predicting ischemic heart disease and stroke in survivors of childhood cancer

Posted by on Mar 10, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study investigated the individual risk of ischemic heart disease and stroke through age 50 in 5-year survivors of childhood cancer. The authors concluded that these conditions can be reasonably predicted using information available after childhood cancer therapy. Some background For the 400,000 childhood cancer survivors in the...

Read More

Rituximab treatment for elderly patients with aggressive B-cell lymphomas

Posted by on Mar 10, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study looked at the impact of rituximab treatment and gene mutations on the outcomes for elderly patients who did not respond to first line chemotherpy. The study concluded that patients who experienced treatment failure after first line rituximab and chemotherapy had poor outcomes, but rituximab improved patient outcomes when...

Read More